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Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity Leukemia (2013) 27, 1789-1791; doi:10.1038/leu.2013.61
We conducted a clinical trial utilizing the platform of proteosome inhibition with bortezomib þ histone deacetylase inhibition with vorinostat in relapsed/refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) based on the potential target of nuclear factor-kappaB. 1, 2 The study rationale was based on published single-agent efficacy of the agents in AML and high-risk MDS, [3] [4] [5] [6] [7] [8] and safety data for the combination in other malignancies. [9] [10] [11] [12] [13] [14] [15] Between August 2009 and May 2012, a total of 16 patients, aged 18 or older, were enrolled on this study at the University of Minnesota. The trial was registered with NCI clinicaltrials.gov no. NCT00818649.
Patients were treated with vorinostat 400 mg daily on days 1-14 and bortezomib 1.3 mg/m 2 IV on days 1,4,8 and 11 of a 21-day cycle. Pretherapy bone marrow assessments and transfusion requirements were documented. Disease response assessments were done after three cycles or at trial exit if fewer than three cycles were completed. Clinical responses were defined as complete morphologic remission (CR), partial remission (PR) and hematologic improvement (HI). Stable disease (SD) and progressive disease (PD) were also noted. Completion of at least one full cycle was required to be evaluable for analysis of clinical response. All patients were included in toxicity assessment.
Bryant and Day's two-stage Phase II was used for this study to monitor both response rate and toxicity. On the basis of this twostage optimal design, a maximum of 46 patients with high-risk MDS and relapsed/refractory AML were needed. Of them, 21 patients were to be accrued during stage I, and 25 patients during stage II. Excess toxicity was defined as any toxicity that required permanently stopping the study drug, required three or more dose reductions, or where patient death occurred that was possibly attributable to the study therapy and not due to PD. Specific stopping rules were in place for the study. For stage 1, the study would be terminated for failed efficacy if only one patient had a clinical response or for toxicity if eight or greater had excess toxicity. SAS 9.2 (Cary, NC, USA) was used for the statistical analyses.
A total of 16 patients began therapy, but only 12 completed at least one cycle of therapy to be eligible for response evaluation. The patients were at a median age of 65.5, were 50% female and predominantly white (94%). Karnofsky performance status was a median of 85 (range 70-100). Medically significant comorbidities for the entire patient cohort included vascular disease (predominantly cardiac n ¼ 4), chronic obstructive pulmonary disease (n ¼ 1), prior gastrointestinal bleed (n ¼ 1), prior fungal infection (n ¼ 2), Crohn's disease (n ¼ 1), long-term fever of unknown origin (n ¼ 1, diabetes (n ¼ 1) and neuropathy (n ¼ 2). Of the 12 patients evaluable for response, 8 had AML and 4 had MDS. Those with AML were primary induction failures (PIF) (n ¼ 3), untreated elderly patients unfit for standard induction (n ¼ 1), or those who relapsed post allogeneic stem cell transplant or natural killer cellular therapy (n ¼ 4). Cytogenetics for those with AML were complex (n ¼ 3), normal (n ¼ 2), 7q-(n ¼ 1) or miscellaneous abnormalities (n ¼ 2). Median blast burden for AML patients was 44% (range 11-90). All MDS patients had PD after prior hypomethylating agents and had refractory anemia of excess blasts-2 (RAEB-2) with complex (n ¼ 2), normal (n ¼ 1) or unknown (n ¼ 1) cytogenetics.
Of the 12 patients evaluable for response, 50% (n ¼ 6) completed all three cycles, with the majority requiring some dose reduction, 2 patients completed therapy through cycle 2, and 4 patients completed cycle 1 before disease progression or termination due to toxicity. The overall clinical response (CR, PR or HI) was 8%, with only one patient obtaining a morphologic CR. The remainder had either SD (n ¼ 5) or PD (n ¼ 6). The PIF AML patient achieving a CR remained transfusion independent for B6 months post therapy completion before evidence of disease progression. Of the five patients with SD, one remained without disease progression for nearly 1 year after therapy completion. At the time of analysis there were no surviving patients. All patients died with active disease.
Toxicity was common (Table 1 ) with a total of 165 nonhematologic events documented during the time of treatment and within 30 days of followup. Nausea, vomiting, diarrhea, anorexia, metabolic disturbances, liver function test abnormalities and QT prolongation were the most common events. The majority (n ¼ 162, 98%) were grade 3 or less. Additional less common adverse events included dizziness, dehydration and constipation. Infectious complications were minimal, with pneumonia (n ¼ 2), neutropenic infection/fever (n ¼ 3) and perirectal abscess (n ¼ 1) being the only documented infections. There were three severe (grade 5) events (presumed to be cardiac) that led to unexpected death during treatment. The first event involved an RAEB-2 patient with extensive prior cardiac history, including numerous cardiac stents, who was admitted with neutropenic fever, sepsis and developed hypotension, elevated troponins/presumed ischemia, and died after resuscitation events were unsuccessful. The second incident involved a patient with refractory AML post failed natural killer cellular therapy who was admitted with fevers, hypoxia and pulmonary infiltrates, and was later found unresponsive in his hospital room and subsequently died with active disease. Because of these two events the study was temporarily suspended for evaluation by our Data Safety Monitoring Committee. After thorough investigation it was felt that the initial two events had multifactorial causes and weren't definitively linked to study drug; thus, the study was reopened with the addition of more stringent protocol that required cardiac evaluation thereafter. After study reopening an elderly MDS patient successfully completed all three cycles of therapy with minimal toxicity. Unfortunately, a final unexpected severe adverse event occurred in an AML patient relapsed post allogeneic stem cell transplant who tolerated cycle 1 and cycle 2 (days 1 and 4) without complication before developing an abnormal breathing pattern at home and subsequent asystolic arrest in route to the hospital via ambulance. This patient subsequently died with active AML. After the final death, the study was stopped because of excess toxicity, which was defined as comprising eight treatment-limiting events. The overall excess toxicity rate was 50% (8 of 16 patients).
Preclinical and phase I data with single-agent vorinostat or bortezomib in myeloid malignancies and a strong scientific rationale for the drug combination led to optimism towards a clinical trial combining these two agents in AML and MDS. Our study results revealed that the combination produced stability of disease in a subset of patients and a CR in one. These results suggest modest clinical activity of this drug combination in myeloid diseases. Unfortunately, significant toxicity limited additional cycles of therapy in some responding patients and greater than expected cardiac toxicity was observed.
The significant toxicities, including unexpectedly high cardiac events, noted in this trial were surprising given the overall favorable toxicity profile in similar studies with myeloma and mantle cell lymphoma. [11] [12] [13] [14] [15] There are many potential reasons for this. Our patient populations, especially those with AML, were heavily pretreated, with a median of three prior lines of therapy, and over half relapsed post allogeneic stem cell transplant. Although the majority of patients had a reasonable performance status (4KPS 80), it is likely that the heavy pretreatment impacted their further reserve to tolerate toxicity. Regarding the cardiac toxicity, we saw the expected complication of low-grade QT prolongation in nine, but also three acute unexpected events leading to death (one with extensive prior cardiac history developing hypotension and elevated troponin and presumed Abbreviations: Alk phos, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase. A total of 165 non-hematologic adverse events were noted in all 16 treated patients. The table includes the most common or significant adverse events. Those other events that had six or fewer instances were not included. Metabolic disturbances include: hyponatremia (n ¼ 4), hypernatremia (n ¼ 2), hypokalemia (n ¼ 4) and hypocalcemia (n ¼ 2).
Letters to the Editor cardiac ischemia in the setting of sepsis, and two with unexpected episodes of some form of cardiopulmonary arrest in patients with no known cardiac history). Interestingly, there was a very distinct dichotomy of patient toxicity profiles. Patients either had minimal toxicity and completed all or close to all cycles of therapy or had unexpectedly high toxicity and completed only 1-2 cycles. There was no apparent pattern of pretreatment patient characteristics, such as age or disease status, which predicted this toxicity response. This raises the question of possible differences in drug metabolism or processing. Unfortunately, we did not capture clinical samples that would allow for such investigation. Overall responses and survival in the patient population were disappointing. Because of disease progression and toxicity, there were no patients surviving past 1 year, indicating the high-risk nature of this group of patients. However, while overall responses only yielded a CR in one, five patients had SD, one of which had disease stability for nearly a year post therapy completion. Given the treatment challenge of relapsed/refractory AML and high-risk MDS, the development of outpatient chemotherapy combinations that could serve as maintenance therapy for long-term AML control is an attractive option. For our studied drug combination, if the toxicity prediction were possible, the vorinostat and bortezomib combination could have been successful therapy for disease stability. Unfortunately, our study was closed to accrual early due to toxicity, so further study in this specific setting is not possible. Future study of novel combinations should include sample collection assessing for drug metabolism/pharmacodynamics, which may predict toxicity exposure and could then identify patients with potential benefit with improved treatment tolerability.
